Cited by 108Diabetes Treatment and ManagementHeart Failure Treatment and ManagementBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials

Open access

Lin, Donna Shu-Han, Lee, Jen-Kuang, Hung, Chi-Sheng, Chen, Wen-Jone·2021·Diabetologia

DOI 10.1007/s00125-021-05529-w

Open this paper in CoChat — free account Open PDF

Abstract

Aims/hypothesis Several cardiovascular outcome trials on sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been released recently, including trials enrolling patients with congestive heart failure (CHF) and chronic kidney disease (CKD). Comparisons of the efficacy and safety of SGLT2i, glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) thus require an update. Assessments in patient subgroups, i.e., as stratified by age or the presence of CHF, CKD or atherosclerotic cardiovascular disease (ASCVD), are also currently lacking.Methods We searched the PubMed, Embase and Cochrane databases for relevant studies published up until 5 December 2020. RCTs comparing SGLT2i, GLP-1RA and DPP-4i with placebo (or other controls) or with each other with cardiovascular (CV) or renal outcomes were eligible for inclusion. The primary efficacy endpoint was 3-point major adverse cardiovascular events (3P-MACE), which are defined as CV death, non-fatal myocardial infarction and non-fatal ischaemic stroke. All-cause mortality, hospitalisation for heart failure (HHF) and composite renal outcomes were also analysed. Pre-specified subgroup analyses of 3P-MACE were also performed.Results A total of 21 trials with 170,930 participants were included in this network meta-analysis. Both GLP-1RA and SGLT2i were associated with lower risks of 3P-MACE than placebo (RR 0.89, 95% CI 0.84, 0.94 and RR 0.88, 95% CI 0.83, 0.94, respectively). GLP-1RA and SGLT2i were also associated with lower risks of 3P-MACE than DPP-4i (RR 0.89, 95% CI 0.82, 0.98 and RR 0.89, 95% CI 0.81, 0.97, respectively). A comparison between SGLT2i and GLP-1RA demonstrated no difference in their risks of 3P-MACE (RR 0.99, 95% CI 0.91, 1.08). Only GLP-1RA was associated with a lower risk of stroke compared with placebo (RR 0.85, 95% CI 0.76, 0.94). SGLT2i is superior to GLP-1RA in reducing HHF (RR 0.76, 95% CI 0.68, 0.84) and renal outcomes (RR 0.78, 95% CI 0.65, 0.93). Subgroup analyses indicated that the benefits of SGLT2i and GLP-1RA were more pronounced in elderly patients, white and Asian patients, those with established ASCVD and those with longer durations of diabetes mellitus and worse glycaemic control.Conclusions/interpretation SGLT2i and GLP-1RA are superior to DPP-4i in terms of CV and renal outcomes. GLP-1RA is the only drug class that reduces the risk of stroke. SGLT2i is superior in reducing HHF and renal outcomes. Therefore, the choice between SGLT2i and GLP-1RA should be individualised according to patient profiles.Prospero registration number CRD42020206600.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-021-05529-w

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206

Show all 37 references

Sorted by citations

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K. M., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100679 · Cited by 181
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Giugliano, D., Longo, M., Signoriello, S., Maiorino, M. I., Solerte, B., Chiodini, P., & Esposito, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01474-z · Cited by 153
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels
D’Andrea, E., Wexler, D. J., Kim, S. C., Paik, J. M., Alt, E. M., & Patorno, E. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6664 · Cited by 105
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Navaneethan, S. D., Bansal, N., Cavanaugh, K. L., Chang, A. R., Crowley, S. T., Delgado, C., Estrella, M. M., Ghossein, C., Ikizler, T. A., Koncicki, H. M., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.003 · Cited by 116
Socioeconomic aspects of incretin-based therapy
Karagiannis, T., Bekiari, E., & Tsapas, A. (2023) · Diabetologia · doi:10.1007/s00125-023-05962-z · Cited by 91
Aging and Cardiovascular Disease: Current Status and Challenges
Zhou, M., Zhao, G., Zeng, Y., Zhu, J., Cheng, F., & Liang, W. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304135 · Cited by 91
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 61
Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Barchetta, I., Cimini, F. A., Dule, S., & Cavallo, M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10092306 · Cited by 60
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Lin, T., Kang, E. Y., Shao, S., Lai, E. C., Garg, S. J., Chen, K., Kang, J., Wu, W.-C., Lai, C., & Hwang, Y. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0221 · Cited by 48
Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
Wei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 48
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin
Shin, H., Schneeweiß, S., Glynn, R. J., & Patorno, E. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4012 · Cited by 44
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, W., Xu, L., Zhang, H., & Li, Y. (2022) · BMJ · doi:10.1136/bmj-2021-068882 · Cited by 43
Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., & Chen, W. (2022) · Diabetologia · doi:10.1007/s00125-022-05772-9 · Cited by 38
Self-citation
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Lonardo, A. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.07 · Cited by 32
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01877-6 · Cited by 33
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
Parab, P. T., Chaudhary, P., Mukhtar, S., Moradi, A., Kodali, A., Okoye, C., Klein, D., Mohamoud, I., Olanisa, O. O., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.45487 · Cited by 31
Efficacy of GLP ‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Yin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 33
GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy
Holst, J. J., Jepsen, S. L., & Modvig, I. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102189 · Cited by 26
Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study
Sharma, A., Wood, S. J., Bell, J. S., Blasio, M. J. D., Ilomäki, J., & Ritchie, R. H. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100692 · Cited by 21
The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond
Mudaliar, S. R. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-023-00357-w · Cited by 22
Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis
Zhang, L., Zhang, F., Bai, Y., Huang, L., Zhong, Y., & Zhang, X. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003836 · Cited by 20
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Scheen, A. J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101474 · Cited by 20
Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 16
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
Scheen, A. J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2354885 · Cited by 16
Diabetes Mellitus Treatment
Khoo, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00079-x · Cited by 17
Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 18
Differential effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose–response meta-analysis involving 10 randomized clinical trials and 71 553 individuals
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., Chiang, F., & Tu, Y. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad078 · Cited by 16
Self-citation
Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 16
Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
Sohn, M., Nam, S., Nauck, M. A., & Lim, S. K. (2024) · BMC Medicine · doi:10.1186/s12916-024-03483-z · Cited by 18
Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: systematic review and meta-analysis
Bilal, A., Yi, F., Gonzalez, G. R., Ali, M., Im, K., Ruff, C. T., Thethi, T. K., & Pratley, R. E. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108783 · Cited by 14
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · Cardiology Research · doi:10.14740/cr1459 · Cited by 14
The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review
Rahman, A., Alqaisi, S., Saith, S. E., Al-Zakhari, R., & Levy, R. (2023) · Cardiology Research · doi:10.14740/cr1523 · Cited by 13
Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes
Jensen, S. K., Heide‐Jørgensen, U., Andersen, I. T., Bonnesen, K., Fu, E. L., Thomsen, R. W., & Christiansen, C. F. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.7409 · Cited by 13
GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes
Huang, T., Bosi, A., Faucon, A., Grams, M. E., Sjölander, A., Fu, E. L., Xu, Y., & Carrero, J. J. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.3806 · Cited by 10
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
Nomoto, H., Takahashi, A., Nakamura, A., Kurihara, H., Takeuchi, J., Nagai, S., Taneda, S., Miya, A., Kameda, H., Cho, K. Y., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002988 · Cited by 11
Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes? a comparison between Asian versus White patients
Scheen, A. J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-54 · Cited by 9
Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes
Siriyotha, S., Lukkunaprasit, T., Looareesuwan, P., Nimitphong, H., McKay, G. J., Attia, J., & Thakkinstian, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01641-2 · Cited by 9
Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives
STOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 9
Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study
Kosjerina, V., Parsa, M., Scheuer, S. H., Ankarfeldt, M. Z., Sørensen, K. K., Brock, B., Vistisen, D., Clemmensen, K. K. B., & Rungby, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103162 · Cited by 9
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes
Sørensen, K. K., Yazdanfard, P. D. W., Zareini, B., Pedersen‐Bjergaard, U., Kosjerina, V., Andersen, M. P., Munch, A., Ohlendorff, J. S., Schmid, S., Lanzinger, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02915-1 · Cited by 8
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
Nunns, M., Febrey, S., Buckland, J., Abbott, R. A., Whear, R., Bethel, A. C., Boddy, K., Shaw, L., Coon, J. T., & Meléndez‐Torres, G. J. (2024) · Health Technology Assessment · doi:10.3310/skht8119 · Cited by 9
Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients
Rea, F., Savaré, L., Valsassina, V., Ciardullo, S., Perseghin, G., Corrao, G., & Mancia, G. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01786-8 · Cited by 9
Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 10
Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England
Connolly, D. L., Collins, E., Ren, H., Ming, S. W. Y., Davidson, J. A., & Bain, S. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01715-w · Cited by 7
Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease
Lin, D. S., Lee, J., Huang, K., Lin, T., & Lo, H.-Y. (2024) · Diabetologia · doi:10.1007/s00125-024-06257-7 · Cited by 10
Self-citation
SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
Qiu, M., Xu-bin, W., & Wei, W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.791311 · Cited by 7
Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
Hu, S., Wang, S., Qi, C., Gu, S., Shi, C., Mao, L., & Fan, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831364 · Cited by 7
Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?
Eriksson, J. W., Eliasson, B., Bennet, L., & Sundström, J. (2022) · Diabetologia · doi:10.1007/s00125-022-05762-x · Cited by 7
Therapy of Type 2 Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 5
Predictive performance of established cardiovascular risk scores in the prediabetic population: external validation using the UK Biobank data set
Li, M., Lin, Y., Zhong, X., Huang, R., Zhang, S., Liu, M., Liu, S., Ye, X., Xu, X., Huang, Y., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad106 · Cited by 6
Development and validation of Empagliflozin and Linagliptin simultaneous estimation in rat plasma using freezing lipid precipitation and SCX-SPE assisted HPLC–MS/MS method and its application in pharmacokinetic studies
Thallapalli, A. K. G., & Manda, R. M. (2023) · Analytical Sciences · doi:10.1007/s44211-023-00444-z · Cited by 5
Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions
Zhu, J., Wilding, J. P. H., & Gu, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2135 · Cited by 8
Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
Du, L., Qin, J., Wang, D., Zhao, Y., Xu, N., & Wu, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.987025 · Cited by 5
Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study
Xie, Z., Gan, B., Cao, W., Liu, J., & Chen, J. (2025) · Obesity · doi:10.1002/oby.70065 · Cited by 4
Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes
Huang, L., Hu, R., & Zou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419729 · Cited by 4
Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus
Bu, F., Wu, R., Ostropolets, A., Aminorroaya, A., Chen, H. Y., Chai, Y., Dhingra, L. S., Falconer, T., Hsu, J. C., Kim, C., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5123 · Cited by 3
Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia
Deng, S., Zhao, H.-Y., Chai, S., Sun, Y., Shen, P., Lin, H., & Zhan, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369908 · Cited by 3
Secondary stroke prevention beyond antiplatelets: The role of colchicine and GLP-1RA – an ounce of prevention is worth a pound of cure
Mijajlovic, M. D., Bornstein, N. M., & Aleksić, V. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251326769 · Cited by 3
The effect of bariatric surgery on diabetes related foot complications among patients with type 2 diabetes: A systematic review
Wang, Z., Crowe, F. L., Tahrani, A. A., Singh, P., Wang, J., Tan, L., Nirantharakumar, K., & Hazlehurst, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108813 · Cited by 3
Guía mexicana de práctica clínica para el diagnóstico y tratamiento en pacientes adultos con diabetes tipo 2
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2023) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 2
Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
Tansawet, A., Looareesuwan, P., Teza, H., Boongird, S., McKay, G. J., Attia, J., Pattanaprateep, O., & Thakkinstian, A. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01522-6 · Cited by 2
Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study
Chen, T., Wang, T.-H., Tsai, M., Lin, M., Tsai, T., Chou, T., Tseng, C.-J., Dai, J.-W., Cheng, C.-W., Yang, N., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112205 · Cited by 3
A Nationwide Danish Comparative Effectiveness Study of GLP ‐1 RA , SGLT2i and DPP ‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes
Hastrup, S., Hedegaard, J. N., Andersen, G., Osler, M., Rungby, J., & Johnsen, S. P. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70165 · Cited by 2
Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Gao, W., Cai, X., Wang, X. D., & Li, P. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580095 · Cited by 3
Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy
Niazi, S., Gnesin, F., Jawad, B. N., Niazi, Z., Yazdanfard, P. D. W., Toft‐Petersen, A. P., Sørensen, K. K., Meaidi, A., Subhi, Y., & Torp-Pedersen, C. T. (2026) · Acta Ophthalmologica · doi:10.1111/aos.70168 · Cited by 2
Evaluation of Clinical and Quality of Life Effects of Oral Semaglutide Use in Type 2 Diabetes from a Public Health View: A Prospective Study in Italy
Pantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
Du, L., Zhang, Y., Wang, P., Li, Z., & Zhao, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1034095 · Cited by 2
Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
Singh, A. K., & Shah, V. N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0037 · Cited by 3
Safety and cardiometabolic efficacy of novel antidiabetic drugs
Michaud, L., Seplowe, M., Meir, J., & Aronow, W. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2188190 · Cited by 2
Do SGLT2 inhibitors protect elderly patients from HF rehospitalization and CKD progression? More opportunities than concerns
Galassi, A., Cara, A., Magagnoli, L., Faccioli, F. M., & Cozzolino, M. G. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.155 · Cited by 2
Therapie des Typ-2-Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 1
Evolution of Management of Diabetes Mellitus
Uddin, K. N. (2024) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v35i1.70738 · Cited by 1
Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff
Liu, B., Wu, X., Zou, X., Sheng, J., & Yu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-96545-y · Cited by 1
Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease
Barber, T., Neumiller, J. J., Fravel, M. A., Page, R. L., II, & Tuttle, K. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf045 · Cited by 1
Genetic analysis of the correlation between GLP1 action and metabolic liver disease: Insights from Mendelian randomization analysis
Ma, Z., Wang, B., Li, D., & Chen, X. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70087 · Cited by 1
Heme oxygenase-1 polymorphisms associate with ischemic cardiac complications and all-cause mortality in type 1 diabetes
Segersvärd, H., Sandholm, N., Harjutsalo, V., Tikkanen-Dolenc, H., Kosonen, R., Laine, M., Tikkanen, I. T., Groop, P.-H., Lakkisto, P., & the FinnDiane Study Group (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02895-2 · Cited by 1
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
An, X., Li, X., Zhang, H., Jia, Q.-Y., Zhang, Y., & Yang, G.-G. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.111280 · Cited by 1
Sex differences in cardiovascular and renal outcomes with sodium–glucose cotransporter 2 inhibitors: a meta-analysis of randomized controlled trials
Lin, D. S., Lo, H.-Y., Huang, K.-C., Lin, T., Huang, C.-Y., Lee, J.-K., & Lin, L. (2026) · European journal of medical research · doi:10.1186/s40001-026-03849-4 · Cited by 1
Self-citation
Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c
German, J., Huang, W. A., Brucker, A., Daniel, K., Halpern, D. J., Bhavsar, N. A., Hinz, E. M., Shannon, R., Pignone, M. P., Crowley, M. J., et al. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005546 · Cited by 1
Therapie des Typ-2-Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Development of a selective novel fluorescent substrate for sodium-dependent transporters
Agnes, R. S., Traughber, B. J., & Muzic, R. F. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122847 · Cited by 1
Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke
Du, L., Wang, P., Chen, H., Zhang, Y., & Ma, J. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.08.223 · Cited by 1
Special Issue on Metabolism and Metabolite Markers in Type 2 Diabetes
Eriksson, J. W. (2022) · Metabolites · doi:10.3390/metabo12070642
Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?
Du, L., Qin, J., & Zhang, Y. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14878
Prescrição de inibidores do cotransportador de sódio-glicose 2 em portadores de insuficiência cardíaca: uma revisão de literatura
Guimarães, H. J. E., da Silva, V. R. R., Oliveira, C. R. V., & Reis, B. C. C. (2022) · Revista Eletrônica Acervo Médico · doi:10.25248/reamed.e11201.2022
De cómo la serendipia y la investigación traslacional han revolucionado el tratamiento de la diabetes mellitus y de otras enfermedades
Gimeno, E. J. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/2022.3/art1
I nuovi farmaci antidiabetici nelle persone che vivono con l’infezione da HIV.
Mirani, M. (2023) · JHA - Journal of HIV and Ageing · doi:10.19198/jha31553
Dapagliflozin
CADTH (2023) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2023.732
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
Keskinler, M. V., Çaklılı, Ö. T., & Oğuz, A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00290-5
How to Use Type 2 Diabetes Treatments in Clinical Practice
Karagiannis, T., Liakos, A., & Τσάπας, Α. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch37
Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks
Fonseca, P. E. O., Azevedo, J. A., Bié, S. M. G., & Ferreira, S. B. (2024) · Archives of Pharmacy and Pharmaceutical Sciences · doi:10.29328/journal.apps.1001055
The Risk of Heart Failure by Partially Mediating Systolic Blood Pressure With Glinides And Sulfonylureas: Insights from a Drug Mendelian Randomization StudyPreprint
Tang, C., Lin, Y., Yang, C., Li, H., Li, L., Liu, Y., Zhou, X., Zeng, L., Zhang, L., & Yuan, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4941301
Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
Oya, J., Shimizu, M., Kubota, R., Suda, R., & Nakagami, T. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14391
Research Progress on the Relationship between Blood Glucose Related Indicators and Adverse Consequences after Myocardial Infarction
张, 子. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42155
Additional file 1 of Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
Sohn, M., Nam, S., Nauck, M. A., & Lim, S. (2024) · Figshare · doi:10.6084/m9.figshare.26157034
Additional file 1 of Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Figshare · doi:10.6084/m9.figshare.23597476

Authors: Lin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J.
Affiliations: National Taiwan University Hospital (TW)
National Taiwan University (TW)
Corresponding author: Hung, Chi-Sheng
ORCID: Lin, Donna Shu-Han
Lee, Jen-Kuang
Hung, Chi-Sheng
Chen, Wen-Jone
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2021-09-18
Volume: 64
Issue: 12
Pages: 2676-2686
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-021-05529-w
OpenAlex: W3199651111
Cited by: 108
References: 37
Citations by year: 2026: 13 · 2025: 19 · 2024: 25 · 2023: 25 · 2022: 25 · 2021: 1
FWCI: 2.91
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Funders: Ministry of Science and Technology, Taiwan (MOST 109, 109-2221-E, 2221-E-002, MOST108-2221-E002-163, MOST 108-, MOST109-2221-E002-083, MOST 109-2221)
National Taiwan University Hospital (109-EDN11, 108‐N4406, 108‐EDN02, 107-EDN11, 109-O20, 109-S4579)
National Taiwan University
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: antidiabetic drugs, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, major adverse cardiovascular events, cardiovascular outcomes, heart failure hospitalization, renal outcomes, chronic kidney disease, atherosclerotic cardiovascular disease, congestive heart failure, subgroup analysis, drug safety, type 2 diabetes
MeSH terms: Glucagon-Like Peptide-1 Receptor, Network Meta-Analysis, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Brain Ischemia, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents, Stroke, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks